Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.37 |
| ▸ | PDE2A | O00408 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | NNMT | P40261 | 1/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21859884 | 0.78 | HTT (0.44) | TSHRKDM4EXBP1NPSR1HTT | |
| SCHEMBL21055249 | 0.77 | TSHR (0.39) | TSHRKDM4EXBP1NPSR1HTT | |
| SCHEMBL5391265 | 0.77 | TSHR (0.39) | TSHRKDM4EXBP1NPSR1HTT | |
| SCHEMBL21859496 | 0.76 | TSHR (0.38) | TSHRKDM4EXBP1NPSR1HTT | |
| SCHEMBL21055330 | 0.74 | TSHR (0.37) | TSHRKDM4EXBP1NPSR1HTT | |
| SCHEMBL21859512 | 0.74 | PDE10A (0.41) | TSHRKDM4EXBP1NPSR1PDE10A | |
| SCHEMBL21725475 | 0.74 | TSHR (0.37) | TSHRKDM4EXBP1NPSR1HTT | |
| SCHEMBL3543895 | 0.74 | NNMT (0.61) | KDM4EPDE10AGAANNMT | |
| SCHEMBL31709840 | 0.74 | KDM4E (0.33) | KDM4EHTTHSD17B10GAA | |
| SCHEMBL14938661 | 0.74 | HSP90AA1 (0.39) | TSHRKDM4EHTTHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776445-B1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-08-10 | — | — | EP | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-8901141-B2 | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
| EP-2240485-B1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8785460-B2 | Tricyclic compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2240485-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Pharmaceutical Company Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009093747-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-7250418-B2 | Compounds as CRF1 receptor antagonists | PFIZER INC (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250418-B2 | Compounds as CRF1 receptor antagonists | PFIZER INC (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250418-B2 | Compounds as CRF1 receptor antagonists | PFIZER INC (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1583531-B1 | HETEROARYL-SUBSTITUTED PYRROLO[2, 3- B]PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-03-22 | — | — | US | disclosed |
| EP-1625125-A1 | COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS | Pharmacia & Upjohn Company LLC (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-1583531-A1 | HETEROARYL- SUBSTITUTED PYRROLO' 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB Pharmco Puerto Rico Inc (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050038040-A1 | Compounds as CRF1 receptor antagonists | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2004099201-A1 | COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004062665-A1 | HETEROARYL- SUBSTITUTED PYRROLO` 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | CRHR1, CRHR2, CRH | TSHR 271/4885KDM4E 4352/4885XBP1 3169/4885 |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | TSHR 2062/4885KDM4E 1652/4885XBP1 581/4885 |
| US-20050038040-A1 | Compounds as CRF1 receptor antagonists | CRHR1, CRHR2, CRH | TSHR 409/4885KDM4E 4497/4885XBP1 1648/4885 |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | TSHR 145/4885KDM4E 2435/4885XBP1 1792/4885 |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRH, CRHR1, CRHR2 | TSHR 62/4885KDM4E 3544/4885XBP1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.